Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes

被引:13
|
作者
Lu, Xinyan [1 ]
Sun, Dongli [1 ]
Chen, Zhongjian [1 ]
Ye, Jianfei [2 ]
Wang, Ruwei [2 ]
Li, Liping [1 ]
Zeng, Su [1 ]
Jiang, Huidi [1 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, Dept Pharmaceut Anal & Drug Metab, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Conba Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China
来源
PHARMAZIE | 2011年 / 66卷 / 08期
关键词
MORIFOLIUM EXTRACT; IN-VITRO; FLAVONOIDS; METABOLISM; PLASMA; LIVER; CONJUGATION; ABSORPTION; ENZYMES; HPLC;
D O I
10.1691/ph.2011.1517
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The hepatic clearance and drug-drug interactions of luteolin and apigenin were studied by using primary cultured rat hepatocytes. Luteolin and apigenin experienced extensive first-pass metabolism. The elimination percent of luteolin and apigenin was found to be 91.9% and 86.7% after 120 min of incubation. The predicted % liver blood flow was 82.3% and 85.4% for luteolin and apigenin, respectively. Total glucuronidated/sulfated conjugates of luteolin/apigenin were determined by an enzyme hydrolysis method. Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin. The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied. At least four key determinants in the chemical structures of flavonoids are necessary for exerting the inhibitory effects on the conjugation: 1) catechol structure (3',4'-dihydroxylation) in the B-ring; 2) B-ring is attached to the C-2 position on the C-ring; 3) the C2-3 double bond in conjunction with the C4 carbonyl group on the C-ring; 4) no glycoside present. Investigation of clearance and interaction among flavonoids could help us better understand their bioavailability and offer insight into the approaches to be taken to minimize competitive effects, and to design appropriate bioavailability studies in humans.
引用
收藏
页码:600 / 605
页数:6
相关论文
共 50 条
  • [1] Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models
    Liang, You
    Sun, Bo
    Yang, Min
    Meng, Xiaona
    Wang, Meng
    Yang, Lijuan
    AI-Hamyari, Bandar
    Zhang, Yuqian
    Shen, Yutong
    Meng, Shengnan
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2025, 20 : 2557 - 2573
  • [2] Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: Studies of digoxin metabolism in primary rat hepatocytes versus microsomes
    Lam, JL
    Benet, LZ
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (11) : 1311 - 1316
  • [3] Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes
    Lin, Christine
    Shi, Julianne
    Moore, Amanda
    Khetani, Salman R.
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (01) : 127 - 136
  • [4] Elimination of luteolin and apigenin in hydrolyzed chrysanthemum morifolium extract in primary cultured rat hepatocytes
    Lu, Xin-yan
    Jiang, Hui-di
    Zeng, Su
    DRUG METABOLISM REVIEWS, 2006, 38 : 111 - 111
  • [5] Elimination of luteolin and apigenin in hydrolyzed chrysanthemum morifolium extract in primary cultured rat hepatocytes
    Lu, Xin-yan
    Jiang, Hui-di
    Zeng, Su
    DRUG METABOLISM REVIEWS, 2006, 38 : 144 - 145
  • [6] Cryopreserved Human Hepatocytes for the Prediction of Metabolic Clearance and Drug-Drug Interactions in Humans; An Update
    Alexandre, Eliane
    Pekthong, Dumrongsak
    Baze, Audrey
    Parmentier, Celine
    Bachellier, Philippe
    Mantion, Georges
    Heyd, Bruno
    Hewitt, Nicola
    Richert, Lysiane
    DRUG METABOLISM REVIEWS, 2009, 41 : 46 - 46
  • [7] Cryopreserved HUMAN Hepatocytes as A MODEL for the EVALUATION of TOXICITY and Drug-Drug Interactions
    Richert, Lysiane
    Baze, Audrey
    Desbans, Coraline
    Parmentier, Celine
    Heyd, Bruno
    Mantion, Georges
    Bachellier, Philippe
    Weber, Jean-Christophe
    Zacharias, Thomas
    Simon, Sandrine
    Ungell, Anna-Lena
    Annaert, Pieter
    Alexandre, Eliane
    DRUG METABOLISM REVIEWS, 2010, 42 : 76 - 76
  • [8] Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies
    Williamson, Beth
    Riley, Robert J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (12) : 1237 - 1250
  • [9] Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin
    A.P. Li
    M. Jurima-Romet
    Cell Biology and Toxicology, 1997, 13 : 365 - 374
  • [10] Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin
    Li, AP
    JurimaRomet, M
    CELL BIOLOGY AND TOXICOLOGY, 1997, 13 (4-5) : 365 - 374